FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
Prevention and early detection trials have been especially vulnerable to being disrupted by the COVID-19 lockdown, and a comparison of two regimens for monitoring pancreatic cysts—EA2185—was more vulnerable than most.
Prevention and early detection studies frequently require engaging physicians from specialties other than oncologists, said Peter O’Dwyer and Mitchell Schnall, co-chairs of ECOG-ACRIN Cancer Research Group.
Randall F. Holcombe has a goal: earn the NCI designation for University of Vermont Cancer Center. Or, to be precise, earn back the NCI designation.
NIH may be “constrained” in investigating sexual misconduct at NIH-funded institutions once alleged perpetrators are no longer affiliated with these institutions, NIH officials implied in their response to a congressional inquiry on sexual misconduct (The Cancer Letter, Sept. 24, 2021).
Matthew Zachary, a 25-year cancer survivor and founder of Stupid Cancer, didn’t always know what it meant to be a cancer advocate, or the complex and rich history behind the term.
NCI has renewed the Harold C. Simmons Comprehensive Cancer Center’s comprehensive designation.
Fran Visco never asked for $300 million in breast cancer research funding—she demanded it.
On Aug. 5, two months into her job as CEO of the American Cancer Society, Karen Knudsen was in Burlington, VT, checking out the Hope Lodge—the third one she visited since taking the job.
When Ben Harder and his team of health analysts at U.S. News & World Report developed a suite of health equity measures for America’s hospitals, they expected to find some level of disparity, but nothing prepared them for the shocking magnitude of inequity they uncovered.
